Why Is ARROWHEAD PHARMACEUT (ARWR) Stock Down Today?

Arrowhead Pharmaceuticals (ARWR) shares fell 19.07% to close at $47.07 on Monday. The sharp decline followed the company’s presentation of clinical data for its RNAi-based therapies at the American Heart Association (AHA) 2026 Scientific Sessions. While the results showed significant reductions in acute pancreatitis rates, the stock sold off heavily during the session.

What Happened

Arrowhead announced that its investigational drug plozasiran achieved a 78% reduction in acute pancreatitis events versus placebo in late-stage studies. The company also reported that plozasiran sustained triglyceride reductions. Additionally, data for ARO-DIMER-PA showed it lowered LDL cholesterol and triglycerides. Despite these promising clinical outcomes, the stock faced valuation challenges. The company also disclosed that it refinanced its existing credit facility with a new $400 million loan from Sixth Street, which cuts borrowing costs and boosts financial flexibility. Arrowhead is scheduled to webcast its 2026 fiscal year-end results.

What The Data Shows

The stock opened at $58.33 and hit a session high of $58.59 at 7:05 AM ET before sliding to a low of $47.01 at 10:30 AM ET. Trading volume reached 1.9 million shares, which is 1.0 times the three-month daily average. The company has a market capitalization of $8.2 billion and remains unprofitable with a trailing twelve-month EPS of -2.28. Revenue grew 16.8% over the same period, but the net margin stands at -47.8%. The stock has a beta of 1.37 and trades within a 52-week range of $37.06 to $95.49. On November 9, 2026, the stock printed 13 fresh 52-week lows. Over the last 8 sessions, the stock moved -3.4% from $60.21 to $58.16. Recent insider activity includes two sales totaling $1.2 million by directors Olukotun Adeoye Y and Perry Michael S in August 2026, with no buys recorded in the last 90 days.

What To Watch

Investors will monitor the company’s upcoming 2026 fiscal year-end results webcast. The stock’s recent valuation challenges and the market’s reaction to the AHA data will likely remain key factors in near-term price action.